Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • long-term survival
Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis
Posted inClinical Updates news Oncology

Long-Term Survival Following Cytoreductive Surgery and HIPEC for Pseudomyxoma Peritonei: Insights from a 22-Year Single Institution Experience and Contemporary Evidence Synthesis

Posted by MedXY By MedXY 11/06/2025
22-year single-center data confirm CRS and HIPEC as safe, effective for PMP, yielding 62% 5-year survival. Prognostic factors, optimized HIPEC regimens, and perioperative management impact outcomes and recurrence.
Read More
Long-Term Survival Outcomes After Initial Stress Testing Versus Coronary CTA in Suspected CAD: Insights from the PROMISE Trial
Posted inCardiology news

Long-Term Survival Outcomes After Initial Stress Testing Versus Coronary CTA in Suspected CAD: Insights from the PROMISE Trial

Posted by MedXY By MedXY 09/27/2025
The PROMISE trial's 10-year follow-up shows no difference in all-cause or cardiovascular mortality between initial functional stress testing and anatomic coronary CTA in symptomatic patients with suspected coronary artery disease.
Read More
Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols
Posted inClinical Updates news

Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols

Posted by MedXY By MedXY 08/23/2025
A secondary analysis of three total therapy clinical trials reveals significant long-term survival improvements in multiple myeloma patients with modern combinational and stem cell transplant approaches incorporating immunomodulatory and proteasome inhibitors.
Read More
Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients
Posted inClinical Updates Hematology-Oncology Medical News Specialties

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

Posted by MedXY By MedXY 08/01/2025
A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.
Read More
  • Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification
  • Maternal Nipocalimab Therapy for Severe HDFN: Evidence of Neonatal Safety and Immunological Recovery
  • Wearable TEAS Device Outperforms Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting
  • Decoding Antidepressant Response: Genetic and Phenotypic Markers of Treatment Complexity and Sustained Use
  • Substantial Residual Risk and High Costs Persist in HFrEF Despite Optimal Quadruple Therapy at Discharge
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in